Europe Plasma Protein Therapeutics Market Introduction and Overview
According to SPER Market Research, the Europe Plasma Protein Therapeutics Market is estimated to reach USD 16320.44 million by 2033 with a CAGR of 6.12%.
The report includes an in-depth analysis of the Europe Plasma Protein Therapeutics Market, including market size and trends, product mix, distribution channels, and supplier analysis. A class of medications known as plasma protein therapies is derived from proteins present in human blood plasma. These proteins provide a variety of biological tasks for the body, such as controlling immunological response, blood coagulation, and fluid balance. A variety of illnesses, such as bleeding disorders, immunological deficits, and genetic abnormalities, are treated with plasma protein therapies. They must be closely monitored to guarantee correct dosage and reduce any possible adverse effects. They are frequently given by injection or infusion.
Grifols opened a brand-new, cutting-edge production facility in Ireland in October 2022 to fulfill the rising demand for plasma therapies worldwide. The most abundant plasma protein, albumin, is in greater demand than ever, therefore Grifols' Dublin manufacturing facility triples the yearly filling capacity of its novel, flexible container, ALBUTEIN FlexBag. The Rika Plasma Donation System (Rika), created by Terumo Blood and Cell Technologies (Terumo BCT), a medical technology business, was approved by the Food and Drug Administration (FDA) in March 2022.
Market Opportunities and Challenges
Opportunities: The rising incidence of autoimmune diseases, immune deficiency illnesses, neurological and bleeding disorders, and the expansion of plasma protein research and development are the main drivers of the market's growth. Furthermore, normal blood clotting is hindered by the rare inherited bleeding condition hemophilia. Uncontrolled bleeding, often in several body parts, is the primary sign of this condition. The degree of hemophilia dictates how much bleeding occurs. Future growth in the market is anticipated since hemophilia is becoming more and more common among patients. Additionally, throughout the course of the forecast period, rising corporate activities and research and development (R&D) of novel treatments are anticipated to support segment expansion.
Challenges: The European market for plasma protein therapeutics is faced with some significant challenges. First of all, the licensing and commercialization of products produced from plasma are frequently delayed by regulatory obstacles and strict quality standards, which restricts market access for both existing and growing businesses. Furthermore, variations in the demand and supply of plasma, which are impacted by variables including donor accessibility and prevailing economic conditions, can cause delays in manufacturing schedules and shortages in the material. Market share and pricing strategies are also threatened by the growing competition from biosimilar drugs and other treatment techniques. Moreover, patient access to plasma protein therapies may be restricted by reimbursement concerns and healthcare budgetary restraints in certain European nations, which may have an effect on market expansion.
Market Competitive Landscape
The Plasma Protein Therapeutics Market in Europe is moderately consolidated. Some of the market key players are Abeona Therapeutics Inc., ADMA Biologics Inc., Baxter International Inc., Bayer AG, CSL Limited (CSL Behring), Grifols, S.A., Kedrion S.p.A, Octapharma AG, Taibang Biological Group Co., Ltd, Takeda Pharmaceutical Company Limited, Others.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By End User, By Product Type, By Application
|
| Regions covered | UK, France, Germany, Italy, Spain, Rest of Europe
|
| Companies Covered | Abeona Therapeutics Inc., ADMA Biologics Inc., Baxter International Inc., Bayer AG, CSL Limited (CSL Behring), Grifols, S.A., Kedrion S.p.A, Octapharma AG, Taibang Biological Group Co., Ltd, Takeda Pharmaceutical Company Limited, Others.
|
COVID-19 Impact on Europe Plasma Protein Therapeutics Market
The early stages of the COVID-19 pandemic had a major effect on the plasma protein therapies business due to factors like decreased plasma donations, lab and testing center closures, and import and export restrictions on medications. But once the limitations were removed, the industry has been thriving again. Due to more product launches for plasma protein therapies and related research investigations, the market is anticipated to expand.
Key Target Audience:
- Healthcare Providers
- Pharmaceutical Companies
- Research Institutions
- Regulatory Agencies
- Patients
- Distributors
- Investors
Our in-depth analysis of the Europe Plasma Protein Therapeutics Market includes the following segments:
|
By End User: |
Hospitals
Others
|
|
By Product Type: |
Immunoglobulin
Albumin
Plasma derived factor VIII
Other
|
|
By Region:
|
Idiopathic Thrombocytopenic Purpura
Primary Immunodeficiency Disorder
Others
|
Key Topics Covered in the Report:
- Europe Plasma Protein Therapeutics Market Size (FY’2024-FY’2033)
- Overview of Europe Plasma Protein Therapeutics Market
- Segmentation of Europe Plasma Protein Therapeutics Market By End User (Hospitals, Others)
- Segmentation of Europe Plasma Protein Therapeutics Market By Product Type (Immunoglobulin, Albumin, Plasma derived factor VIII, Other)
- Segmentation of Europe Plasma Protein Therapeutics Market By Application (Idiopathic Thrombocytopenic Purpura, Primary Immunodeficiency Disorder, Others)
- Expansion Analysis of Europe Plasma Protein Therapeutics Market
- Problems and Obstacles in Europe Plasma Protein Therapeutics Market
- Competitive Landscape in the Europe Plasma Protein Therapeutics Market
- Impact of COVID-19 and Demonetization on Europe Plasma Protein Therapeutics Market
- Details on Current Investment in Europe Plasma Protein Therapeutics Market
- Competitive Analysis of Europe Plasma Protein Therapeutics Market
- Prominent Players in the Europe Plasma Protein Therapeutics Market
- SWOT Analysis of Europe Plasma Protein Therapeutics Market
- Europe Plasma Protein Therapeutics Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Europe Plasma Protein Therapeutics Market
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Europe Plasma Protein Therapeutics Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Europe Plasma Protein Therapeutics Market
7. Europe Plasma Protein Therapeutics Market, By End User (USD Million) 2020-2033
7.1. Europe Plasma Protein Therapeutics Market Size, Share and Forecast, By End User, 2020-2026
7.2. Europe Plasma Protein Therapeutics Market Size, Share and Forecast, By End User, 2027-2033
7.3. Hospitals
7.4. Others
8. Europe Plasma Protein Therapeutics Market, By Product Type (USD Million) 2020-2033
8.1. Europe Plasma Protein Therapeutics Market Size, Share and Forecast, By Product Type, 2020-2026
8.2. Europe Plasma Protein Therapeutics Market Size, Share and Forecast, By Product Type, 2027-2033
8.3. Immunoglobulin
8.4. Albumin
8.5. Plasma derived factor VIII
8.6. Other
9. Europe Plasma Protein Therapeutics Market, By Application (USD Million) 2020-2033
9.1. Europe Plasma Protein Therapeutics Market Size, Share and Forecast, By Application, 2020-2026
9.2. Europe Plasma Protein Therapeutics Market Size, Share and Forecast, By Application, 2027-2033
9.3. Idiopathic Thrombocytopenic Purpura
9.4. Primary Immunodeficiency Disorder
9.5. Others
10. Europe Plasma Protein Therapeutics Market Forecast, 2020-2033 (USD Million)
10.1. Europe Plasma Protein Therapeutics Market Size and Market Share
11. Europe Plasma Protein Therapeutics Market, By Region, 2020-2033 (USD Million)
11.1. Europe Plasma Protein Therapeutics Market Size and Market Share By Region (2020-2026)
11.2. Europe Plasma Protein Therapeutics Market Size and Market Share By Region (2027-2033)
11.3. France
11.4. Germany
11.5. Italy
11.6. United Kingdom
11.7. Rest of Europe
12. Company Profile
12.1. Abeona Therapeutics Inc.
12.1.1. Company details
12.1.2. Financial outlook
12.1.3. Product summary
12.1.4. Recent developments
12.2. ADMA Biologics Inc.
12.2.1. Company details
12.2.2. Financial outlook
12.2.3. Product summary
12.2.4. Recent developments
12.3. Baxter International Inc.
12.3.1. Company details
12.3.2. Financial outlook
12.3.3. Product summary
12.3.4. Recent developments
12.4. Bayer AG
12.4.1. Company details
12.4.2. Financial outlook
12.4.3. Product summary
12.4.4. Recent developments
12.5. CSL Limited (CSL Behring)
12.5.1. Company details
12.5.2. Financial outlook
12.5.3. Product summary
12.5.4. Recent developments
12.6. Grifols, S.A.
12.6.1. Company details
12.6.2. Financial outlook
12.6.3. Product summary
12.6.4. Recent developments
12.7. Kedrion S.p.A
12.7.1. Company details
12.7.2. Financial outlook
12.7.3. Product summary
12.7.4. Recent developments
12.8. Octapharma AG
12.8.1. Company details
12.8.2. Financial outlook
12.8.3. Product summary
12.8.4. Recent developments
12.9. Taibang Biological Group Co., Ltd
12.9.1. Company details
12.9.2. Financial outlook
12.9.3. Product summary
12.9.4. Recent developments
12.10. Takeda Pharmaceutical Company Limited
12.10.1. Company details
12.10.2. Financial outlook
12.10.3. Product summary
12.10.4. Recent developments
12.11. Others
13. List of Abbreviations
14. Reference Links
15. Conclusion
16. Research Scope